The effects of contemporary treatment of DCIS on the risk of developing an ipsilateral invasive Breast cancer (iIBC) in the Dutch population
Sena Alaeikhanehshir(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital), Jelle Wesseling(Leiden University Medical Center), Alexandra W. van den Belt‐Dusebout(The Netherlands Cancer Institute), Ellen Verschuur(Borstkankervereniging Nederland), Frederieke van Duijnhoven(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital), Esther H. Lips(Oncode Institute), Michael Schaapveld(The Netherlands Cancer Institute), Renée Schmitz(The Netherlands Cancer Institute), Maartje van Seijen(The Netherlands Cancer Institute)
Cited by 7
Related Papers
(untitled)
|Edinburgh Research Explorer|0|353
Magnetic Resonance Imaging Response Monitoring of Breast Cancer During Neoadjuvant Chemotherapy: Relevance of Breast Cancer Subtype
|Journal of Clinical Oncology|2011|306
Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER)
|The Lancet Oncology|2007|278
The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer
|Breast Cancer Research and Treatment|2009|256
Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers
|British Journal of Cancer|2013|241